Table 3.

Prevalence rate ratio of polypharmacy and excessive polypharmacy in 2014.

	Polypharmacy			Excessive polypharmacy
	Ratea	PRR	95% CI	Ratea	PRR	95% CI
Gender
Male	17.3	1		4.5	1
Female	20.7	1.20	1.20–1.20	5.7	1.26	1.25–1.26
Age group
< 60	8.5	1		1.4	1
60–69	35.9	4.52	4.50–4.54	9.2	6.99	6.93–7.05
70–79	54.8	7.61	7.57–7.64	17.0	14.32	14.20–14.44
80–89	73.0	8.01	7.96–8.05	29.0	19.32	19.14–19.49
90+	79.6	11.24	11.13–11.36	36.4	31.21	30.78–31.66
Education, year
0–9	21.3	1		6.2	1
10–11	19.2	0.90	0.90–0.90	5.2	0.82	0.82–0.83
12+	16.5	0.77	0.77–0.77	4.1	0.66	0.65–0.66
Birth country
Sweden	18.9	1		5.0	1
Northern European country	20.1	1.06	1.05–1.07	6.0	1.19	1.17–1.21
Western European country	15.2	0.80	0.79–0.81	4.1	0.83	0.81–0.85
Eastern European country	18.8	0.99	0.99–1.00	6.0	1.21	1.19–1.22
African country	16.8	0.89	0.87–0.90	4.5	0.90	0.87–0.92
Middle-Eastern country	23.0	1.21	1.20–1.22	8.1	1.63	1.61–1.65
Others	16.8	0.89	0.88–0.89	5.0	1.00	0.99–1.01

^aRates were adjusted according to the Swedish population distribution in 2006.